Schizophrenia treatment in the developing world: An interregional and multinational cost-effectiveness analysis

Bulletin of the World Health Organization

Volumn 86, Issue 7, 2008, Pages 542-551

  Chisholm, Dan ^a   Gureje, Oye ^b   Saldivia, Sandra ^c   Calderón, Marcelo Villalón ^d   Wickremasinghe, Rajitha ^e   Mendis, Nalaka ^f   Ayuso Mateos, Jose Luis ^g   Saxena, Shekhar ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF IBADAN   (Nigeria)

^c UNIVERSITY OF CONCEPCIÓN   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

^e UNIVERSITY OF KELANIYA   (Sri Lanka)

^f UNIVERSITY OF COLOMBO   (Sri Lanka)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

COST-BENEFIT ANALYSIS; DEVELOPING WORLD; DISEASE SEVERITY; DRUG; HEALTH IMPACT; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILE; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISABILITY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN RIGHTS; MAJOR CLINICAL STUDY; MALE; NIGERIA; POPULATION RESEARCH; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA; SRI LANKA; WORLD HEALTH ORGANIZATION;

AFRICA, WESTERN; ANTIPSYCHOTIC AGENTS; ASIA, SOUTHEASTERN; COMMUNITY MENTAL HEALTH SERVICES; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; HEALTH CARE COSTS; HUMANS; MENTALLY ILL PERSONS; MODELS, ECONOMETRIC; MODELS, ORGANIZATIONAL; PSYCHOTHERAPY; PUBLIC HEALTH INFORMATICS; QUALITY-ADJUSTED LIFE YEARS; SCHIZOPHRENIA; SOUTH AMERICA; WORLD HEALTH ORGANIZATION;

EID: 46449135338     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.07.045377     Document Type: Article

References (41)

1. Mental health: new understanding, new hope. Geneva: WHO; 2001.
2. Adams CE, Awad G, Rathbone J, Thornley B. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 1998;1; Art. No. CD000284. doi: 10.1002/14651858.CD000284.pub2
3. Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software.
4. Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 2000;57:987-94.
5. Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. Pharmacoeconomics 1999;15:469-80.
6. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693-702.
7. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87.
8. Xiong W, Phillips MR, Hu X, Wang R, Dai Q, Kleinman J, et al. Family-based intervention for schizophrenic patients in China: a randomised controlled trial. Br J Psychiatry 1994;165:239-47.
9. Healey A, Knapp MRJ, Astin J, Beecham JK, Kemp R, Kirov G, et al. Cost-effectiveness evaluation of compliance therapy for people with psychosis. Br J Psychiatry 1998;172:420-4.
10. WHO regions. Available from: http://www.who.int/choice/demography/regions [accessed on 29 April 2008].
11. Evans DB, Tan-Torres Edejer T, Adam T, Lim S for the WHO-CHOICE MDG Team. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ 2005;331:1137-40.
12. Tan-Torres Edejer T, Baltussen RM, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: WHO; 2003.
13. Evans DB, Lim S, Adam T, Tan-Torres Edejer T for the WHO-CHOICE MDG Team. Evaluation of current strategies and future priorities for improving health in developing countries. BMJ 2005;331:1457-61.
14. Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry 2004;184:393-403.
15. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003;361:717-25.
16. Shibuya K, Ciecierski C, Guindon E, Bettcher DW, Evans DB, Murray CJ. WHO Framework Convention on Tobacco Control: development of an evidence based global public health treaty. BMJ 2003;327:154-7.
17. Hyman S, Chisholm D, Kessler R, Patel V, Whiteford H. Mental disorders. In: Jamison D, Breman J, Measham A, Alleyne G, Evans D, Jha P et al. (eds.) Disease control priorities in developing countries. 2nd edn. New York: Oxford University Press; 2006.
18. Hutubessy R, Chisholm D, Tan-Torres Edejer T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 2003;1:8.
19. Reinap M, Lai T, Janno S, Tamme T, Tamm M. Cost-effectiveness of mental health interventions in Estonia [Project report]. Tallinn: Healthcare Association; 2005.
20. Gutierrez-Recacha P, Chisholm D, Haro JM, Salvador-Carulla L, Ayuso-Mateos JL. Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain. Acta Psychiatr Scand 2006;114 s432;29-38.
21. Gureje O, Chisholm D, Kola L, Lasebikan V, Saxena S. Cost-effectiveness of an essential mental health intervention package in Nigeria. World Psychiatry 2007;6:42-8.
22. Ayuso-Mateos JL. Global burden of schizophrenia in the year 2000 [Global Burden of Disease working paper]. Geneva: WHO. Available from: http://www.who.int/evidence/bod [accessed on 18 April 2008].
23. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001;178:506-17.
24. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11-53.
25. Ayuso-Mateos JL, Gutierrez-Recacha P, Haro J, Chisholm D. Estimating the prevalence of schizophrenia in Spain using a disease model. Schizophr Res 2006;86:194-201.
26. Vicente B, Kohn R, Rioseco P, Saldivia S, Levav I, Torres S. Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study. Am J Psychiatry 2006;163:1362-70.
27. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005;2:e141.
28. Wijesinghe CP, Dissanayake SAW, Dassanayake PVLN. Survey of psychiatric morbidity in a semi-urban population in Sri Lanka. Acta Psychiatr Scand 1978;58:413-41.
29. Andrews G, Sanderson K, Corry J, Issakidis C, Lapsley H. Cost-effectiveness of current and optimal treatment of schizophrenia. Br J Psychiatry 2003;183:427-35.
30. Sanderson K, Andrews G, Corry J, Lapsley H. Using the effect size to model change in preference values from descriptive health status. Qual Life Res 2004;13:1255-64.
31. Mojtabai R, Nicolson RA, Carpenter BN. Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies. Schizophr Bull 1998;24:569-87.
32. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
33. Chatterjee S, Patel V, Chatterjee A, Weiss HA. Evaluation of a community-based rehabilitation model for chronic schizophrenia in rural India. Br J Psychiatry 2003;182:57-62.
34. Srinivasa Murthy R, Kishore Kumar KV, Chisholm D, Thomas T, Sekar K, Chandrashekar CR. Community outreach for untreated schizophrenia in rural India: a follow-up study of symptoms, disability, family burden and costs. Psychol Med 2005;35:341-51.
35. Ferri C, Chisholm D, Van Ommeren M, Prince M. Resource utilisation for neuropsychiatric disorders in developing countries: a multinational Delphi consensus study. Soc Psychiatry Psychiatr Epidemiol 2004;39:218-27.
36. Adam T, Evans D, Murray CJ. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 2003;1:3.
37. Baltussen RM, Hutubessy RC, Evans DB, Murray CJ. Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Health Care 2002;18:112-9.
38. Macroeconomics and health: investing in health for economic development. Geneva: WHO; 2001.
39. Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T. Assessing cost-effectiveness of drug interventions for schizophrenia. Aust N Z J Psychiatry 2005;39:44-54.
40. Mihalopoulos C, Magnus A, Carter R, Vos T. Assessing cost-effectiveness in mental health: family interventions for schizophrenia and related conditions. Aust N Z J Psychiatry 2004;38:511-9.
41. Frank R, Koss C. Mental health and labor markets productivity loss and restoration [DCPP working paper no. 38]. February 2005. Available from: http://www.dcp2.org/file/50/wp38.pdf [accessed on 18 April 2008].